drugset / Trial / NCT03234244

HDDO-1614 Intervention Trial

NCT03234244

Phase 1 Completed 37 enrolled Hyundai Pharmaceutical Co., LTD.
RandomizedCrossoverDouble-blindOther

Summary

Randomized, Open-label, Single-dose, 3-period, 6-sequence, 3-way crossover Study

Timeline

Start
2017-04-12
Primary completion
2017-08-14
Completion
2017-08-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bazedoxifene Other / unclassified 20 mg
Comparator Cholecalciferol Other / unclassified

Indications